Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Neoadjuvant Monotherapy With Anti-PD1 Agents in Patients With Resectable Stage IIIB-D Melanoma: Analysis of Novel Biomarkers

NCT06299878 is registered in ClinicalTrials.gov with Russian Academy of Medical Sciences as lead sponsor.

NCT NCT06299878
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06299878 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Neoadjuvant Monotherapy With Anti-PD1 Agents in Patients With Resectable Stage IIIB-D Melanoma: Analysis of Novel Biomarkers
Lead sponsor
Russian Academy of Medical Sciences
Phase
Observational
Overall status
Unknown status
Start date
January 1, 2022
Completion date
July 1, 2025
Enrollment
72 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

melanoma stage iii, melanoma, skin